Joseph Jankovic1, Elijahu Berkovich2, Eli Eyal2, Eduardo Tolosa3. 1. Parkinson's Disease Center and Movement Disorders Clinic, Dept of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: josephj@bcm.tmc.edu. 2. Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel. 3. Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Catalonia, Spain.
Abstract
BACKGROUND: The ADAGIO study included a large cohort of patients with early PD (baseline total-UPDRS = 20) who were initially randomized torasagiline and placebo, thereby allowing analyses of symptomatic efficacy. METHODS: Post-hoc analyses comparing the efficacy of rasagiline 1 mg/day (n = 288) versus placebo (n = 588) on key symptoms at 36 weeks, and on total-UPDRS scores over 72 weeks (completer population: rasagiline 1 mg/day n = 221, placebo n = 392) were performed. RESULTS: Treatment with rasagiline resulted in significantly better tremor, bradykinesia, rigidity and postural-instability-gait-difficulty scores at week 36 versus placebo. Whereas the placebo group experienced progressive deterioration from baseline (2.6 UPDRS points at week 36), patients in the rasagiline group were maintained at baseline values at week 60 (UPDRS-change of 0.3 points). At week 72, patients who had received continuous monotherapy with rasagiline experienced a worsening of only 1.6 points. CONCLUSIONS: Treatment with rasagiline maintained motor function to baseline values for at least a year with significant benefits observed in all key PD motor symptoms.
RCT Entities:
BACKGROUND: The ADAGIO study included a large cohort of patients with early PD (baseline total-UPDRS = 20) who were initially randomized to rasagiline and placebo, thereby allowing analyses of symptomatic efficacy. METHODS: Post-hoc analyses comparing the efficacy of rasagiline 1 mg/day (n = 288) versus placebo (n = 588) on key symptoms at 36 weeks, and on total-UPDRS scores over 72 weeks (completer population: rasagiline 1 mg/day n = 221, placebo n = 392) were performed. RESULTS: Treatment with rasagiline resulted in significantly better tremor, bradykinesia, rigidity and postural-instability-gait-difficulty scores at week 36 versus placebo. Whereas the placebo group experienced progressive deterioration from baseline (2.6 UPDRS points at week 36), patients in the rasagiline group were maintained at baseline values at week 60 (UPDRS-change of 0.3 points). At week 72, patients who had received continuous monotherapy with rasagiline experienced a worsening of only 1.6 points. CONCLUSIONS: Treatment with rasagiline maintained motor function to baseline values for at least a year with significant benefits observed in all key PD motor symptoms.
Authors: Zhuang Wu; Min Zhong; Xu Jiang; Bo Shen; Jun Zhu; Yang Pan; Jingde Dong; Jun Yan; Pingyi Xu; Wenbin Zhang; Yang Gao; Li Zhang Journal: Neuropsychiatr Dis Treat Date: 2020-10-09 Impact factor: 2.570
Authors: Katrijn Smulders; Marian L Dale; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak Journal: Parkinsonism Relat Disord Date: 2016-07-17 Impact factor: 4.891